Drug Profile

ENX 105

Alternative Names: ENX-105

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Engrail Therapeutics
Class Anxiolytics; Mood stabilisers; Small molecules
Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor agonists; Serotonin 5-HT2A receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Feb 2025 Discontinued - Preclinical for Mood disorders in USA (PO) (Engrail Therapeutics pipeline, February 2025)
28 Feb 2025 Discontinued - Preclinical for Post-traumatic stress disorders in USA (PO) (Engrail Therapeutics pipeline, February 2025)
15 Mar 2023 Preclinical trials in Mood disorders in USA (PO) before March 2023 (Engrail Therapeutics pipeline, March 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com